How CJC-1295/Ipamorelin Works in Research Models
CJC-1295 and Ipamorelin are two distinct GH secretagogue peptides studied in combination for synergistic GH release in preclinical and clinical research. CJC-1295 is a GHRH analog with DAC modification for extended half-life, acting at GHRH receptors on pituitary somatotroph cells. Ipamorelin is a selective ghrelin receptor (GHSR-1a) agonist with minimal off-target receptor activity documented in published selectivity research. Published studies have characterized the combined GH pulsatility, IGF-1 axis effects, and body composition endpoints in rodent and primate models.
Mechanism Steps in Research Models
How researchers have characterized CJC-1295/Ipamorelin activity in published preclinical studies.
GHRH Receptor Activation (CJC-1295)
CJC-1295 binds the GHRH receptor on pituitary somatotroph cells, activating Gs protein coupling and cAMP production. Research has characterized increased GH gene expression and secretion following GHRH receptor activation, with the DAC modification of CJC-1295 extending receptor occupancy duration compared to native GHRH.
GHSR-1a Receptor Activation (Ipamorelin)
Ipamorelin activates the ghrelin receptor (GHSR-1a) through a complementary Gq protein pathway, driving IP3-mediated calcium mobilization in somatotrophs. Published selectivity research has documented Ipamorelin with high GHSR-1a selectivity and minimal activity at other receptor subtypes including cortisol and prolactin pathways.
Synergistic GH Release
Published research documents combined GHRH and GHSR-1a receptor activation producing GH pulse amplitude exceeding either compound alone. Researchers have quantified this synergism through direct GH measurement in portal blood and peripheral serum in rodent and primate models, with dose-response characterization across multiple combination ratios.
IGF-1 Axis Activation
Downstream of enhanced GH release, published research documents IGF-1 increases in liver and peripheral tissues of animal models receiving CJC-1295 and Ipamorelin combination protocols. Researchers have measured IGF-1 levels, IGF binding protein profiles, and downstream growth factor signaling in published pharmacodynamic studies.
Research Observations
Key findings documented in published preclinical studies.
GH Pulsatility Research
Published pharmacodynamic studies have documented CJC-1295/Ipamorelin combination producing amplified GH pulses in rodent models, with characterization of pulse amplitude, duration, and frequency parameters relative to single-agent and vehicle control groups.
IGF-1 Axis Studies
Animal model research has documented sustained IGF-1 axis increases following CJC-1295/Ipamorelin combination administration, with published data on tissue-specific IGF-1 expression and IGF binding protein dynamics over multiple administration timepoints.
Body Composition Research
Published preclinical research has examined body composition parameters in rodent models receiving GH secretagogue combinations, documenting lean mass and adipose tissue changes measured through DEXA and histological analysis in published metabolic studies.
Clinical GH Secretagogue Studies
Clinical research examining CJC-1295 and related GHRH analogs has provided pharmacokinetic and pharmacodynamic data documenting GH pulse characteristics in human research subjects, published in endocrinology and clinical pharmacology journals.
Signaling Summary
In research models, CJC-1295 activates GHRH receptors on pituitary somatotrophs, stimulating cAMP-dependent GH gene expression and secretion. Ipamorelin simultaneously activates GHSR-1a through a complementary calcium mobilization pathway. Researchers have documented that dual receptor activation produces additive or synergistic GH release exceeding either compound alone, with downstream IGF-1 axis increases measured in animal models.
Frequently Asked Questions
Source Research-Grade CJC-1295/Ipamorelin
Spartan Peptides supplies research-grade CJC-1295/Ipamorelin at least 98% HPLC-verified purity with Certificate of Analysis. Domestic US supply, same-day dispatch before 2 PM. For in vitro research use only.
For in vitro research use only. Not for human consumption.